Connection
Tatiana Kutateladze to Antiviral Agents
This is a "connection" page, showing publications Tatiana Kutateladze has written about Antiviral Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.632 |
|
|
|
-
Zhang Y, Kutateladze TG. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2. Nat Commun. 2020 06 10; 11(1):2920.
Score: 0.452
-
Pandey K, Acharya A, Pal D, Jain P, Singh K, Durden DL, Kutateladze TG, Deshpande AJ, Byrareddy SN. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2. Antiviral Res. 2024 07; 227:105904.
Score: 0.148
-
Acharya A, Pathania AS, Pandey K, Thurman M, Vann KR, Kutateladze TG, Challagundala KB, Durden DL, Byrareddy SN. PI3K-a/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron. Clin Transl Med. 2022 04; 12(4):e806.
Score: 0.032